Screening of liver-targeted drugs

Expert Opinion on Drug Discovery

Volumn 3, Issue 6, 2008, Pages 643-654

  Midorikawa, Yutaka ^a,b   Sugiyama, Yasuyuki ^a   Aburatani, Hiroyuki ^b  

^a TEIKYO UNIVERSITY HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Copy number alterations; Epigenesis; Gene therapy; Liver cancer; Proteomics; Therapeutic target

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 5 AZA 2' DEOXYCYTIDINE; A 7241A; ALPHA FETOPROTEIN; B 2318C; BETA CATENIN; BEVACIZUMAB; GENDICINE; IMATINIB; K 252A; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A23; MONOCLONAL ANTIBODY GPC3; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PLACEBO; SEMAXANIB; SORAFENIB; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GENE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; DNA METHYLATION; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INTERACTION; GENE SILENCING; GENE TARGETING; GENOME ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LUNG METASTASIS; MICROARRAY ANALYSIS; NONHUMAN; NUMERICAL CHROMOSOME ABERRATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEOMICS; REVIEW; SINGLE DRUG DOSE; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE; VIRUS HEPATITIS; VIRUS VIRULENCE;

EID: 45949098088     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.6.643     Document Type: Review

References (108)

1. Berns EM, Klijn JG, van Putten WL, et al. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 1992;52:1107-13
2. Paterson MC, Dietrich KD, Danyluk J, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 1991;51:556-67
3. Seshadri R, Matthews C, Dobrovic A, et al. The significance of oncogene amplification in primary breast cancer. Int J Cancer 1989;43:270-2
4. McNeil C. Herceptin in the adjuvant setting: phase III trials begin. J Natl Cancer Inst 2000;92:683-4
5. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-8
6. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7
7. Butte A. The use and analysis of microarray data. Nat Rev Drug Discov 2002;1:951-60
8. Hsu IC, Metcalf RA, Sun T, et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427-8
9. Zhang X, Xu HJ, Murakami Y, et al. Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994;54:4177-82
10. Yamada T, De Souza AT, Finkelstein S, et al. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci USA 1997;94:10351-5
11. Zhang XK, Huang DP, Qiu DK, et al. The expression of c-myc and c-N-ras in human cirrhotic livers, hcpatocellular carcinomas and liver tissue surrounding the tumors. Oncogene 1990;5:909-14
12. Nishida N, Fukuda Y, Komeda T, et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 1994;54:3107-10
13. Hsu HC, Jeng YM, Mao TL, et al. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000;157:763-70
14. Boix L, Rosa JL, Ventura F, et al. c-met mRNA overexpression in human hepatocellular carcinoma. Hepatology 1994;19:88-91
15. Midorikawa Y, Makuuchi M, Tang W, et al. Microarray-based analysis for hepatocellular carcinoma: from gene expression profiling to new challenges. World J Gastroenterol 2007;13:1487-92
16. Midorikawa Y, Tang W, Sugiyama Y. High-resolution mapping of copy number aberrations and identification of target genes in hepatocellular carcinoma. Biosci Trends 2007;1:26-32
17. Moinzadeh P, Breuhahn K, Stutzer H, et al. Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade - results of an explorative CGH meta-analysis. Br J Cancer 2005;92:935-41
18. Villanueva A, Newell P, Chiang DY, et al. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007;27:55-76
19. Calvisi DF, Ladu S, Gorden A, et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007;117:2713-22
20. Rauch TA, Zhong X, Wu X, et al. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci USA 2008;105:252-7
21. Jacinto FV, Ballestar E, Ropero S, et al. Discovery of epigenetically silenced genes by methylated DNA immunoprecipitation in colon cancer cells. Cancer Res 2007;67:11481-6
22. Ge H. UPA, a universal protein array system for quantitative detection of protein-protein, protein-DNA, protein-RNA and protein-ligand interactions. Nucleic Acids Res 2000;28:e3
23. Chignard N, Beretta L. Proteomics for hepatocellular carcinoma marker discovery. Gastroenterology 2004;127:S120-5
24. Kallioniemi OP, Wagner U, Kononen J, et al. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001;10:657-62
25. Wingren C, Borrebaeck CA. Antibody microarrays: current status and key technological advances. Omics 2006;10:411-27
26. Ma H, Horiuchi KY. Chemical microarray: a new tool for drug screening and discovery. Drug Discov Today 2006;11:661-8
27. Castel D, Pitaval A, Debily MA, et al. Cell microarrays in drug discovery. Drug Discov Today 2006;11:616-22
28. Stock P, Monga D, Tan X, et al. Platelet-derived growth factor receptor-alpha. a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther 2007;6:1932-41
29. Zhang T, Sun HC, Xu Y, et al. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer Res 2005;11:8557-63
30. Eckel F, von Delius S, Mayr M, et al. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology 2005;69:363-71
31. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits turnor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-8
32. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300
33. Llovet J RS, Mazzaferro V. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-contorolled trial (SHARP trial) [abstract LBA1]. J Clin Oncol (Meeting Abstracts) 2007;25(18S)
34. Matoba K, Iizuka N, Gondo T, et al. Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma. Int J Cancer 2005;115:231-40
35. Yoshida K, Tomita Y, Okuda Y, et al. Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol 2006;13:159-67
36. Wang W, Yang LY, Huang GW, et al. Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer 2004;90:2349-55
37. Cheung ST, Leung KL, Ip YC, et al. Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma. Clin Cancer Res 2005;11:551-6
38. Wurmbach E, Chen YB, Khitrov G, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007;45:938-47
39. Chen X, Cheung ST, So S, et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002;13:1929-39
40. Cheung ST Wong SY, Leung KL, et al. Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. Clin Cancer Res 2004;10:7629-36
41. Ho JC, IP YC, Cheung ST, et al. Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology 2008;47:1524-32
42. Okabe H, Furukawa Y, Kato T, et al. Isolation of development and differentiation enhancing factor-like 1 (DDEFL1) as a drug target for hepatocellular carcinomas. Int J Oncol 2004;24:43-8
43. Yagyu R, Hamamoto R, Furukawa Y, et al. Isolation and characterization of a novel human gene, VANGL1, as a therapeutic target for hepatocellular carcinoma. Int J Oncol 2002;20:1173-8
44. Ito H, Funahashi S, Yamauchi N, et al. Identification of ROBO1 as a novel hepatocellular carcinoma antigen and a potential therapeutic and diagnostic target. Clin Cancer Res 2006;12:3257-64
45. Midorikawa Y, Ishikawa S, Iwanari H, et al. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 2003;103:455-65
46. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5
47. Yamauchi N, Watanabe A. Hishinuma M, et al. The glypican 3 oncoferal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005;18:1591-8
48. Hippo Y, Watanabe K, Watanabe A, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-srage hepatocellular carcinoma. Cancer Res 2004;64:2418-23
49. Wang XY, Degos F, Dubois S, et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006;37:143541
50. Libbrecht L, Severi T, Cassiman D, et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, clysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006;30:1405-11
51. Kandil D, Leiman G, Allegretta M, et al. Glypican-3 immunocytochemistry in liver fine-needle aspirates: a novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer 2007;111:316-22
52. Okabe H, Satoh S, Furukawa Y, et al. Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Cancer Res 2003;63:3043-8
53. Okabe H, Satoh S, Kato T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001;61:2129-37
54. Silva FP, Hamamoto R, Nakamura Y, et al. WDRPUH, a novel WD-repeat-containing protein, is highly expressed in human hepatocellular carcinoma and involved in cell proliferation. Neoplasia 2005;7:348-55
55. Silva FP, Hamamoto R, Furukawa Y, et al. TIPUH1 encodes a novel KRAB zinc-finger protein highly expressed in human hepatocellular carcinomas. Oncogene 2006;25:5063-70
56. Iida H, Honda M, Kawai HF, et al. Ephrin-A1 expression contributes to the malignant characteristics of {alpha}-fetoprotein producing hepatocellular carcinoma. Gut 2005;54:843-51
57. Anderson SC, Johnson DE, Harris ME et al. p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus. Clin Cancer Res 1998;4:1649-59
58. Mitry RR, Sarraf CE, Havlik R, et al. Detection of adenovinis and initiation of apoptosis in hepatocellular carcinoma cells after Ad-p53 treatment. Hepatology 2000;31:885-9
59. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005;16:1016-27
60. Guan YSSL, Zhou XP, Li X, et al. Combination therapy with recombinant adenovirus-p53 injection (rAd-p53) via transcatheter hepatic arterial chemoembolization for advanced hepatic carcinoma. Shijie Huaren Xiaohua Zazhi 2005;13:125-7
61. Yeh CT, Lu SC, Tseng IC, et al. Antisense overexpression of BMAL2 enhances cell proliferation. Oncogene 2003;22:5306-14
62. Zhang P, Chan DW. Zhu Y, et al. Identification of carboxypeptidase of glutamate like-B as a candidate suppressor in cell growth and metastasis in human hepatocellular carcinoma. Clin Cancer Res 2006;12:6617-25
63. Midorikawa Y, Tsutsumi S, Nishimura K, et al. Distinct chromosomal bias of gene expression signatures in the progression of hepatocellular carcinoma. Cancer Res 2004;64:7263-70
64. Midorikawa Y, Yamamoto S, Ishikawa S, et al. Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays. Oncogene 2006;25:5581-90
65. Bayani J, Brenton JD, Macgregor PF, et al. Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res 2002;62:3466-76
66. Lee SA, Ho C, Roy R, et al. Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate rumor suppressor in liver cancer. Hepatology 2008;47:1200-10
67. Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133:647-58
68. Park WS, Dong SM, Kim SY, et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999;59:307-10
69. Takeo S, Arai H, Kusano N, et al. Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas: comparison with comparative genomic hybridization analysis. Cancer Genet Cytogenet 2001;130:127-32
70. Takayama H, LaRochelle WJ, Sharp R, et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 1997;94:701-6
71. Arena S, Pisacane A, Mazzone M, et al. Genetic targeting of the kinase activity of the Met receptor in cancer cells. Proc Natl Acad Sci USA 2007;104:11412-7
72. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65:1479-88
73. Berthou S, Aebersold DM, Schmidt LS, et al. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 2004;23:5387-93
74. Sattler M, Pride YB, Ma P, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrusine kinase. Cancer Res 2003;63:5462-9
75. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63:7345-55
76. Morotti A, Mila S, Accornero P et al. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 2002;21:4885-93
77. Wang SY, Chen B, Zhan YQ, et al. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J Hepatol 2004;41:267-73
78. Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-depcndent-kinase inhibitor p27Kip1 is instigated byJab1. Nature 1999;398:160-5
79. Berg JP, Zhou Q, Breuhahn K, et al. Inverse expression of Jun activation domain binding protein 1 and cell cycle in p27Kip1: influence on proliferation in hepatocellular carcinoma. Hum Pathol 2007;38:1621-7
80. Patil MA, Gutgemann I, Zhang J, et al. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis 2005;26:2050-7
81. Park SW, Ludes-Meyers J, Zimonjic DB, et al. Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma. Br J Cancer 2004;91:753-9
82. Watanabe A, Hippo Y, Taniguchi H, et al. An opposing view on WWOX protein function as a tumor suppressor. Cancer Res 2003;63:8629-33
83. Huebner K, Croce CM. FRA3B and other common fragile sites: the weakest links. Nat Rev Cancer 2001;1:214-21
84. Kano M, Nishimura K, Ishikawa S, et al. Expression imbalance map: a new visualization method for detection of mRNA expression imbalance regions. Physiol Genomics 2003; 13:3146
85. Ishikawa S, Komura D, Tsuji S, et al. Allelic dosage analysis with genotyping microarrays. Biochem Biophys Res Commun 2005;333:1309-14
86. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54
87. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7
88. Yang B, Guo M, Herman JG, et al. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 2003;163:1101-7
89. Nishida N, Nagasaka T, Nishimura T, et al. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 2008;47:908-18
90. Wong CM, Ng YL, Lee JM, et al. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 2007;45:1129-38
91. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-12
92. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6
93. Yamada T. Takaoka AS, Naishiro Y, et al. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res 2000;60:4761-6
94. Xu L, Corcoran RB, Welsh JW, et al. WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev 2000;14:585-95
95. Gavert N, Conacci-Sorrell M, Gast D, et al. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 2005;168:63342
96. Yamamoto Y, Sakamoto M, Fujii G, et al. Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology 2003;37:528-33
97. Niida A, Hiroko T, Kasai M, et al. DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene 2004;23:8520-6
98. Kato T, Satoh S, Okabe H, et al. Isolation of a novel human gene, MARKL1, homologous to MARK3 and its involvement in hepatocellular carcinogenesis. Neoplasia 2001;3:4-9
99. Chen Y, Guo Y, Ge X, et al. Elevated expression and potential roles of human Sp5, a member of Sp transcription factor family, in human cancers. Biochem Biophys Res Commun 2006;340:758-66
100. Guo Y, Chen Y, Ito H, et al. Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma. Gene 2006;384:51-61
101. Torisu Y, Watanabe A, Nonaka A, et al. A human homolog of Notum, over-expressed in hepatocellular carcinoma, is trariscriptionally regulated by β-catenin/TCF. Cancer Sci 2008; In press
102. Poon TC, Johnson PJ. Proteome analysis and its impact on the discovery of serological tumor markers. Clin Chim. Acta 2001;313:231-9
103. Chen Y, Lin MC, Wang H, et al. Proteomic analysis of EZH2 downstream target proteins in hepatocellular carcinoma. Proteomics 2007;7:3097-104
104. Minagawa H, Honda M, Miyazaki K, et al. Comparative proteomic and transcriptomic profiling of the human hepatocellular carcinoma. Biochem Biophys Res Commun 2008;366:186-92
105. Basu A, Meyer K, Ray RB, et al. Hepatitis C virus core protein is necessary for the maintenance of immortalized human hepatocytes. Virology 2002;298:53-62
106. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998;4:1065-7
107. Basu A, Meyer K, Lai KK, et al. Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. Virology 2006;349:347-58
108. Chan KL, Guan XY, Ng IO. High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. Hum Pathol 2004;35:1324-31